[Biotherapy and biochemotherapy of patients with malignant melanoma].
To evaluate the efficacy of postoperative biochemotherapy on survival of patients with malignant melanoma. One hundred and five patients with malignant melanoma received postoperative biotherapy/biochemotherapy or radiotherapy/chemotherapy. The median time of follow-up was 3 years (from 1 to 5 years). The median survival time (MST) in the whole series of patients was 27 months (range: 2-72 months). The MST in patients received postoperative biotherapy/biochemotherapy (57 cases) was 32 months with a 3-year survival rate of 36.8%. That in patients received postoperative radiotherapy/chemotherapy (54 cases) was 20 months. Biotherapy/biochemotherapy following surgery may significantly improve survival in patients with malignant melanoma.